Sign in
TerminatedPhase 1/2

HPV Specific Immune Lymphocytes (HPV-CTLs) in the Treatment of HPV

Key facts

Who runs it
Shenzhen Geno-Immune Medical Institute
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
Phase
Phase 1/2
People taking part
100 people enrolled
Started
1 Jun 2026
Ended
31 Jul 2026
Type of study
Interventional
Treatments tested
  • HPV-CTLs
Record updated
3 November 2026

Who can take part

Age
6 months to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (15)Hide the full registry criteria

Who can take part

  • Written, informed consent obtained prior to any study-specific procedures
  • Evidence of HPV virus activation (viral DNA) or high risk of HPV infection
  • Not suitable for routine treatment or invalid to antiviral drugs
  • Patients with viral disease symptoms and confirmed by biopsy, regardless of the level of virus DNA
  • Age less than 75 years
  • Did not use Penicillin or β-lactam antibiotics, or the lowest dose of other antibiotics
  • Initial hematopoietic reconstitution: neutrophils (ANC) ≥ 1,000/mm\^3, platelet (PLT) ≥ 1,000/mm\^3
  • Proper renal and hepatic functions (ULN denotes "upper limit of normal range"): Creatinine ≤ 2*ULN, Bilirubin ≤ 2*ULN, SGOT/ SGPT ≤ 3*ULN
  • If HPV-CTL is not from the patient's own, then the provider of HPV-CTL needs to meet the following criteria:; did not receive chemotherapy or radiotherapy within 4 weeks prior to blood collection, and did not take any steroids for the previous week, did not use Penicillin or β-lactam antibiotics, or the lowest dose of other antibiotics; white blood cells ≥ 3,500 / μl, lymphocytes ≥ 750 / μl
  • Human immunodeficiency virus (HIV) test was negative

Who cannot take part

  • Subject participated in other investigational somatic cell therapies within past 30 days
  • Subject or the donor of BMT recipient infected with HCV (HCV antibody positive), HBV (HBsAg positive), HIV (HIV antibody positive), HTLV (HTLV antibody positive), Treponema pallidum antibody positive or TB culture positive
  • Subject is albumin-intolerant
  • Subject with life expectancy less than 8 weeks
  • Subject with positive pregnancy test result

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The purpose of this clinical trial is to evaluate the safety and efficacy of IV-infused autologous or allogenic HPV-CTLs.

The group in the trial

  • HPV-CTLsTreatment being tested

    Autologous or allogenic HPV specific cytotoxic lymphocytes

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Phase I/II and Multicenter Trial of HPV Specific Immune Lymphocytes (HPV-CTLs) in the Treatment of Human Papilloma Virus (HPV) Infection
Record updated
3 November 2026